Author

A. V. Sheahan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

K. L. Morel· 2 shared L. Ellis· 2 shared A. A. Hamid· 1 shared A. D. Choudhury· 1 shared A. Mitrofanova· 1 shared A. Petersen· 1 shared A. S. Kibel· 1 shared A. Sowalsky· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. L. Morel

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology

Targeting RET Kinase in Neuroendocrine Prostate Cancer

H. VanDeusen, J. R. Ramroop, K. L. Morel, A. V. Sheahan, Z. Sychev, N. A. Lau, L. C. Cheng, V. Tan, Z. Li, A. Petersen, J. K. Lee, J. Wook Park, R. Yang, I. Coleman, O. N. Witte, , J. M. Drake

The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.

bioRxiv · Apr 29, 2019Cancer Biology